Merck
CN
  • Post-filler vascular occlusion: a cautionary tale and emphasis for early intervention.

Post-filler vascular occlusion: a cautionary tale and emphasis for early intervention.

Journal of drugs in dermatology : JDD (2013-10-03)
Lindsay K McGuire, Elizabeth K Hale, Loyd S Godwin
ABSTRACT

We report a case of a 36-year-old female who experienced significant vascular occlusion after injection with hyaluronic acid into the nasolabial folds. The patient experienced immediate pain after the injection, however, the vascular compromise was not diagnosed and treated until 48 hours later. The patient suffered tissue damage despite treatment with hyaluronidase, hyperbaric oxygen, nitropaste, and aspirin. The case highlights the importance of proper injection technique by a qualified physician, as well as the need for immediate recognition and treatment of vascular occlusion should it occur.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hyaluronidase from bovine testes, Vetec, reagent grade
Sigma-Aldrich
Hyaluronidase from sheep testes, Type II, lyophilized powder, ≥300 units/mg solid
Sigma-Aldrich
Hyaluronidase from bovine testes, Type IV-S, lyophilized powder (essentially salt-free), 750-3000 units/mg solid
Sigma-Aldrich
Hyaluronidase from bovine testes, Type VI-S, lyophilized powder, 3,000-15,000 units/mg solid
Sigma-Aldrich
Hyaluronidase from bovine testes, Type IV-S, powder, suitable for mouse embryo cell culture, 750-3000 units/mg solid
Sigma-Aldrich
Hyaluronidase from bovine testes, Type VIII, lyophilized powder, 300-1,000 U/mg
Sigma-Aldrich
Hyaluronidase from bovine testes, Type I-S, lyophilized powder, 400-1000 units/mg solid
Sigma-Aldrich
Hyaluronidase from sheep testes, Type V, lyophilized powder, ≥1,500 units/mg solid